Causeway Capital Management WX trades
Sarah Ketterer
Sarah Ketterer WUXI PHARMATECH CAYMAN-ADR stake
total: 372
Trades details
- Total transactions:
- 9
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 3
- Held since:
- 2013 Q3
- Held for:
- 9 quarters
- Latest activity:
- 2015 Q4
According to 2026 Q2 report, Sarah Ketterer doesn't hold any WUXI PHARMATECH CAYMAN-ADR (WX) shares. To date, the estimated cost basis is nearly $31.56 for "buy" trades and estimated average "sell" price is $39.82. Causeway Capital Management first purchased WX in 2013 Q3, initially acquiring 106,600 shares. Since the initial investment in WUXI PHARMATECH CAYMAN-ADR (WX), Causeway Capital Management has made 8 more transactions.
When did Sarah Ketterer sell WUXI PHARMATECH CAYMAN-ADR (WX)?
Sarah Ketterer sold off the entire WUXI PHARMATECH CAYMAN-ADR (WX) position in 2015 Q4.
When did Sarah Ketterer buy WUXI PHARMATECH CAYMAN-ADR (WX)?
Sarah Ketterer first invested in WUXI PHARMATECH CAYMAN-ADR (WX) in 2013 Q3 at the reported quarter-end price of $27.40 per share.
What's the cost basis of Causeway Capital Management's WX stake?
The estimated cost basis for WUXI PHARMATECH CAYMAN-ADR (WX) stake is around $31.56 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $31.56
- Weighted AVG sell price:
- $39.82
Sarah Ketterer's historical trades in WUXI PHARMATECH CAYMAN-ADR
9 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2015 Q4
|
0.00%
|
$43.21
|
-100% (-65,400)
|
|||
|
2015 Q3
|
0.06%
|
$43.21
|
+5.65% (+3,500)
|
|||
|
2015 Q2
|
0.06%
|
$41.53
|
-41.38% (-43,700)
|
|||
|
2015 Q1
|
0.11%
|
$38.78
|
-41.56% (-75,100)
|
|||
|
2014 Q3
|
0.22%
|
$35.02
|
+43.41% (+54,700)
|
|||
|
2014 Q2
|
0.17%
|
$32.86
|
-20.00% (-31,500)
|
|||
|
2014 Q1
|
0.22%
|
$31.37
|
+13.80% (+19,100)
|
|||
|
2013 Q4
|
0.30%
|
$38.38
|
+29.83% (+31,800)
|
|||
|
2013 Q3
|
0.24%
|
$27.40
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.